Evidence map›Paper›PMID 35606864›Full record

ArticleTrials2022

The effect of Rosa canina L. and a polyherbal formulation syrup in patients with attention-deficit/hyperactivity disorder: a study protocol for a multicenter randomized controlled trial.

Haide Golsorkhi, Mostafa Qorbani, Mohammad Kamalinejad, Saeideh Sabbaghzadegan, Mohsen Bahrami, Mohammad Vafaee-Shahi, Hadi Montazerlotfelahi, Elham Abniki, Majid Dadmehr

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Haide GolsorkhiDepartment of Traditional Medicine, Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, Tehran, Iran.
Mostafa QorbaniNon-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Mohammad KamalinejadDepartment of Pharmacognosy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Saeideh SabbaghzadeganDepartment of Traditional Medicine, Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, Tehran, Iran.
Mohsen BahramiResearcher of Persian Medicine, Private clinic, Tehran, Iran.
Mohammad Vafaee-ShahiDepartment of Pediatrics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Hadi MontazerlotfelahiDepartment of Pediatrics, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Elham AbnikiResearcher of Clinical Psychology, Private clinic, Tehran, Iran.
Majid DadmehrDepartment of Traditional Medicine, Research Institute for Islamic and Complementary Medicine, Iran University of Medical Sciences, Tehran, Iran. majiddadmehr@yahoo.com.ORCID http://orcid.org/0000-0002-7032-8648
Iran University of Medical Sciences · IRJahrom University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IR

Funding

Iran University of Medical Sciences 98-2-63-15165
6 · The paper itself

Abstract

backgroundAttention-deficit/hyperactivity disorder (ADHD) is the most common behavioral disorder in childhood and adolescence. A number of these patients do not respond to the current pharmacological treatments and there may also be drug side effects. This study aims to determine the efficacy and safety of two herbal medicine products, including Rosa canina L. (RC) and a polyherbal formulation (PHF) syrup, on the clinical manifestations of ADHD in children and adolescents.

methodsNinety ADHD patients based on DSM-5 diagnostic criteria will be randomly assigned equally into three groups: (1) RC syrup + methylphenidate (MP), (2) PHF syrup + MP, and (3) placebo + MP according to the inclusion criteria (30 subjects in each group). The syrup dosage is 5cc every 8 h, and MP will have a stabilized dose for 8 weeks during the study. Moreover, Conner DISCUSSION: This trial is the first experiment to determine the effects of RC and PHF syrups on the clinical manifestations of ADHD in children and adolescents. Our findings provide new insight into the effect of these herbal products on the clinical manifestations of ADHD.

trial registrationIranian Registry of Clinical Trials IRCT20190923044855N1 . Registered on 14 January 2020. The trial was registered at https://www.irct.ir/ .

Indexed as

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsMethylphenidateRosaAdolescentChildDouble-Blind MethodHumansIranMulticenter Studies as TopicParentsRandomized Controlled Trials as TopicTreatment OutcomeCentral Nervous System StimulantsMethylphenidateADHDAttention-deficit/hyperactivity disorderComplementary and alternative medicinesHerbal medicine

Identifiers

PMID35606864
PMCPMC9125825
OpenAlexW4281294784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.